Crossmark

Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial

Crossref DOI link: https://doi.org/10.1007/s12325-022-02291-2

Published Online: 2022-09-17

Published Print: 2022-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Jiying

Luo, Guogang

Xu, Yuming

Yang, Xiaosu

Pan, Xiaoping

Dong, Zhao

Zhong, Shiying

Liu, Hui

Ji, Fei

Yu, Shengyuan https://orcid.org/0000-0001-8933-088X
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03670810 at ClinicalTrials.gov

Documents that mention this clinical trial

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
https://doi.org/10.1007/s40122-022-00388-8

Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial
https://doi.org/10.1007/s12325-022-02291-2
Funding

Funding for this research was provided by:

Eli Lilly and Company
License Information

Text and Data Mining valid from 2022-09-17

Version of Record valid from 2022-09-17
More Information

Article History

Received: 24 June 2022

Accepted: 29 July 2022

First Online: 17 September 2022

Document is current

Any future updates will be listed below